Kornimate/medical-research-clean huggingface dataset:
effect of tens on acupoints in premenstrual syndrome

Conditions: Premenstrual Pain

Summary: these will be no effect of transcutaneous electrical acupoint stimulation on premenstrual syndrome does transcutaneous electrical acupoint stimulation affect premenstrual syndrome (pms)?

premenstrual syndrome is a collection of emotional, physiological, and behavioral symptoms that develop around the end of the luteal phase and fade away with or after menstruation due to limited evidence on the efficacy of sustained progesterone and the side effects of antidepressant and anxiolytics, in some cases, alternative therapies are recommended for patients with pms teas may be more effective than other forms of transcutaneous electrical nerve stimulation (tens) in modulating brain activity because acupoint areas contain relatively denser neural and neuroactive components than non-acupoint areas teas has been reported to have similar efficacy as acupuncture, electrical acupuncture, and tens

Eligibility criteria:
inclusion criteria: * their age will range from 18 to 25 years. * the regularity of menstrual cycle is 28-35 days. * all of them suffering from moderate and sever pms. * all participants are virgin. * their bmi will range from 25-30 kg\\m2. exclusion criteria: * any pathological findings in the pelvic cavity as pco, endometriosis and pelvic inflammatory disease. * any history of gynecological intervention. * have any condition impedes the use of electrotherapy. * receiving sedatives or any medical treatment. * having irregular menstruation.
dose-finding study to evaluate immunogenicity of three different dose levels of the imvamune (mva-bn) smallpox vaccine.

Conditions: Smallpox

Summary: the objective of the study is to find the optimal dose for the smallpox candidate vaccine imvamune (mva-bn). for this purpose the study compares imvamune (mva-bn) administered at three different dose levels.


Eligibility criteria:
inclusion criteria: * healthy male and female subjects, aged 18 - 30 years * signed informed consent after being advised of the risks and benefits of the study in a language able to understand, and prior to performance of any study specific procedure. * free of obvious health problems with acceptable medical history by screening evaluation and physical examination. * subject of not of child-bearing potential or all of the following: a urine/serum ß-hcg pregnancy test gives a negative result, use of adequate contraceptive precautions for 30 days before first vaccination. exclusion criteria: * known or suspected history of smallpox vaccination or typical vaccinia scar. * positive test result in mva specific elisa or prnt at screening. * positive result in hiv or hcv antibody test at screening. * hbsag positive at screening. * pregnancy or breast-feeding. * uncontrolled serious infection i.e. not responding to antimicrobial therapy * history of any serious medical condition, which in the opinion of the investigator, would compromise the safety of the subject. * history of autoimmune disease * history of malignancy. * history of chronic alcohol abuse and/or intravenous drug abuse. * history of allergic disease or reactions likely to be exacerbated by any component of the vaccine. * history of anaphylaxis or severe allergic reaction. * acute disease (a moderate or severe illness with or without a fever) at the time of enrolment. * any vaccinations within a period starting 30 days prior to administration of the vaccine and ending at study conclusion. * chronic administration of immuno-suppressants or other immune-modifying drugs. * administration or planned administration of immunoglobulins and/or any blood products during the study period. * use of any investigational or non-registered drug or vaccine.
initial human validation of simultaneous dual-tracer cardiac pet imaging

Conditions: Ischemic Heart Disease; Myocardial Infarction

Summary: positron emission tomography (pet) scans can be used to evaluate whether parts of the heart muscle are alive but receiving inadequate blood supply. this study involves the use of two radiotracers that will measure whether heart muscle cell are alive and quantify the blood supply to the heart muscle.

positron emission tomography (pet) scans can be used to evaluate whether parts of the heart muscle (myocardium) are alive but receiving inadequate blood supply. this information can be helpful in identifying the best course of treatment. this type of study involves the use of two radiotracers: rubidium-82 (to measure blood flow) and 18f-fluorodeoxyglucose or fdg (to measure whether heart muscle cells are alive). currently, each of these radiotracers is imaged at separate times, several hours apart. the purpose of this study is to evaluate methods that could allow the entire study to be performed at one time.

Eligibility criteria:
inclusion criteria: 1. 18 years of age or older 2. patients referred for clinically indicated positron emission tomography (pet) viability assessment with rubidium-82 rest perfusion imaging and 18f-fluorodeoxyglucose (fdg) metabolic imaging. exclusion criteria: 1. need for stress perfusion imaging 2. claustrophobia which would prevent positron emission tomography (pet) imaging. 3. inability to lie flat with arms positioned next to the head for approximately 20 minutes. 4. clinical instability such as uncontrolled, potentially life threatening arrhythmias or heart failure requiring mechanical support or infusions of inotropic or vasopressor agents. 5. pregnancy

Keywords: positron emission tomography rubidium myocardial perfusion imaging viability fdg
pet respiratory gating to detect hepatic metastasis in patients with colon cancer

Conditions: Colon Cancer

Summary: this study is to examine if there is improved sensitivity in detecting hepatic lesions using respiratory gating and if there is an improvement in confidence defining lesions as benign or malignant.


Eligibility criteria:
inclusion criteria: * patients with colon cancer * 18 years or older * signed informed consent form * blood glucose of 200 or less prior to scan exclusion criteria: * patients with known hepatic metastasis
comparison of non-mydriatic camera systems in a female health hospital

Conditions: Eye Diseases; Retina; Lesion; Optic Disc Structural Anomaly

Summary: 1. to compare quality and usability of images taken by two different camera-systems without dilating the pupil. 2. to compare the retinal vessel diameters based on the images of to different camera-systems. 3. to detect changes in retinal vessel diameters while pregnancy and after delivery.

1. to compare quality and usability of images taken by two different camera-systems without dilating the pupil. quality means in this content that images cover the planned region of interest and images should be sharp and good illuminated to see details for medical reading of retinal findings. 2. to compare the retinal vessel diameters based on the images of to different camera-systems. the diameters of arteries and veins are planned to be measured with an automated software algorithm. are there differences in the calculated results between the two used camera devices? 3. to detect changes in retinal vessel diameters while pregnancy and after delivery. are there detectable changes of the retinal findings between the images taken before and after delivery (e.g. bleeding, edema, vessel tortuosity)

Eligibility criteria:
inclusion criteria: * written informed consent * age \>18 years * pregnancy (only group 2) exclusion criteria: * limited ability for agreement * heavy tremble * reduced general condition * known epilepsy
developing a screening tool for interstitial lung disease in people with rheumatoid arthritis using risk factors

Conditions: Arthritis, Rheumatoid; Lung Diseases, Interstitial

Summary: the overall aim of the study is to develop and validate a rheumatoid arthritis-interstitial lung disease (ra-ild) clinical prediction model (screening tool) based on risk factors to guide screening for ild in patients with ra using high resolution computed tomography (hrct).


Eligibility criteria:
inclusion criteria: 1. adult patients with ra according to 1987 american college of rheumatology (acr) or 2010 acr / european league against rheumatism (eular) classification of ra, with any ra duration 2. patient must have ≥ 2 of the following risk factors for ild (i.e., any 2 or more): * male * current or previous smoker * age of ≥ 60 years at ra diagnosis * rheumatoid factor high-positive (titer \> 3x upper limit of normal) and/or anti-cyclic citrullinated peptide (anti-ccp) high-positive (titer \> 3x upper limit of normal) at ra diagnosis or any time after ra diagnosis * high/severe ra disease activity score at screening visit or within 12 months of screening visit, as defined with any of the following measures: disease activity score-28 (das-28), clinical disease activity index (cdai), routine assessment of patient index data 3 (rapid-3), simple disease activity index (sdai), patient activity scale (pas), pas-ii * presence or history of these extra-articular manifestations of ra: vasculitis, felty's syndrome, secondary sjogren's syndrome, cutaneous rheumatoid nodules, serositis and/or scleritis/uveitis exclusion criteria: 1. patients previously diagnosed with any ild or interstitial lung abnormality (ila) 2. patients who have had a chest computerized tomography (ct) in the past 2 years 3. pregnancy at time of hrct (to be checked in women of child-bearing potential before scan) 4. unwilling or unable to obtain hrct 5. patients previously received drugs or treatments that are known to induce ild (e.g., radiation therapy to chest region, bleomycin). note: all disease-modifying antirheumatic drugs (dmards) including methotrexate and biologics are allowed. 6. patients who have had a lung transplant 7. patients suspected of having developed ild due to severe acute respiratory syndrome coronavirus 2 (sars-cov-2) infection / coronavirus disease 19 (covid-19) (based on investigators' judgement) 8. patients diagnosed with another autoimmune disorders overlapping with ra-associated with the development of ild (systemic sclerosis, myositis, dermatomyositis, mixed connective tissue disease, systemic lupus erythematosus, antineutrophilic cytoplasmic antibody (anca)-associated vasculitis or primary sjogren's syndrome) 9. patients currently enrolled in an investigational new drug trial
is regular chest physiotherapy an effective treatment in severe, non cystic fibrosis bronchiectasis?

Conditions: Bronchiectasis

Summary: bronchiectasis is a chronic chest condition which causes a persistent cough and frequent chest infections. one of the main forms of treatment is chest physiotherapy. physiotherapy is thought to improve cough and help clear the airways of sticky sputum. traditionally, physiotherapy techniques can be awkward, but recently a new device (a simple mouthpiece, called the acapella device) has been developed to make physiotherapy practise easier. this study aims to assess how helpful regular physiotherapy using a new mouthpiece is in patients with severe bronchiectasis.

study being carried out in the department of respiratory medicine, royal infirmary of edinburgh. the study is entitled "is regular chest physiotherapy an effective treatment in severe, non cystic fibrosis bronchiectasis?" this is a small randomised controlled pilot crossover study assessing the efficacy of regular chest physiotherapy using an acapella mouthpiece in severe non cystic fibrosis bronchiectasis. 10 patients will be randomised to receive full instruction in use of the acapella device (twice daily therapy) and ten patients will continue with their standard treatment regimen. the study will be conducted over seven months. at the beginning we will randomly allocate them to receive either the current standard treatment regimen for bronchiectasis or to receive instruction in the use of the acapella physiotherapy device for the first 3 months. after these 3 months all will receive the current standard treatment regimen for 1 month. following this, those that received current standard treatment will receive acapella physiotherapy device for 3 months and those that received acapella physiotherapy device will stop this and receive current standard treatment for 3 months. all participants will be reviewed on 6 occasions (start of study and then at months 1, 2, 3, 4 and 6). at each review, sputum samples will be collected, routine bloods, spirometry and exercise testing performed and health related quality of life questionnaires be completed. at the end of the study should patients have felt benefit with the physiotherapy with the acapella device, they should continue using it regularly on a twice-daily basis.

Eligibility criteria:
inclusion criteria: * moderate and severe bronchiectasis * no regular chest physiotherapy exclusion criteria: * moderate or severe copd

Keywords: physiotherapy bronchiectasis
can valacyclovir attenuate inflammation in antiretroviral-treated hiv-infected individuals with herpes simplex virus type 2?

Conditions: Human Immunodeficiency Virus; Herpes Simplex

Summary: the purpose of this study is to compare the levels of immune and inflammatory markers among hiv-1, hsv-2 co-infected adults achieving plasma hiv rna suppression to \<50 copies/ml, between those randomized to valacyclovir and placebo, over a twelve-week intervention period.

highly active antiretroviral therapy (haart) has dramatically reduced hiv-1 infection (herein referred to as 'hiv') related morbidity and mortality, transforming an invariably fatal disease into a manageable, chronic condition. yet even haart-treated hiv infection is characterized by chronic systemic inflammation and immune activation. this systemic inflammatory response is composed of multiple components, and can be quantified by measuring markers of immune activation, inflammatory cytokines, acute phase reactants, endothelial activation markers, and markers of microbial translocation. this inflammation is clinically relevant, as it may contribute directly to hiv disease progression and non-aids related morbidity and mortality in hiv-infected patients. because this inflammation persists even in the context of suppressive haart, albeit at modestly decreased levels, adjunctive therapeutic strategies to attenuate this persistent inflammatory response are therefore needed. herpes simplex virus type 2 is a common, clinically important co-infection seen in individuals living with hiv infection, and may contribute to this ongoing inflammation. this pilot trial will investigate whether short-term valacyclovir for hsv-2 suppression can decrease systemic inflammation in haart-treated, hiv-1, hsv-2 co-infected individuals.

Eligibility criteria:
inclusion criteria: * adult (aged 18 years or older) * documented hiv-1 infection (determined by eia and western blot) * documented hsv-2 seropositivity (determined by elisa during screening) * no use of chronic anti-hsv therapy for the past 6 months, and not anticipated to require chronic anti-hsv therapy during the study * sustained plasma hiv rna\<50 copies/ml on haart for at least 12 months * no active opportunistic infection for at least 12 months exclusion criteria: * hepatitis c co-infection * hepatitis b co-infection * pregnancy or actively planning to become pregnant * receiving chemotherapy, chronic steroid therapy or other immunomodulatory medications (e.g. interferon, azathioprine, methotrexate, tnf-alpha antagonists, etc.) * estimated creatinine clearance \<30 ml/min * other medical condition likely to cause death within 24 months * enrolled in any other interventional clinical trial
immunohistochemical study of neurodegenerative diseases

Conditions: Alzheimer Disease; Lewy Body Disease; Neurodegenerative Diseases

Summary: the subject uses cytof to analyze pbmc of sporadic ad and dlb, which is used to reveal the differences in immune characteristics of the two diseases at the single-cell level, build immune models for specific diseases, and define these two neurodegenerative diseases with high precision from the level of molecular immunity. to provide basis for further study of the immunohistochemical differences between the two diseases, and provide objective support for clinical diagnosis and differential diagnosis.


Eligibility criteria:
inclusion criteria: 1. ad inclusion criteria: a.clinical diagnosis of alzheimer's disease 2. dlb inclusion criteria: 1. clinical diagnosis of dementia with lewy bodies exclusion criteria: 1. infectious diseases 2. autoimmune disease 3. heart failure 4. chronic obstructive pulmonary disease (copd) 5. cancer 6. renal failure 7. recently major surgery 8. alcohol and / or drug abuse 9. disturbance of consciousness 10. clinical diagnosis of major depression disorder 11. clinical diagnosis of anxiety disorder
detection of tumor dna in blood samples from patients with early stage cancer and "healthy controls"

Conditions: Neoplasms, Non-hematologic - Stage I-III

Summary: the aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing, currently undergoing or have completed treatment. this approach will allow the investigators to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment.

the aim of this study is to employ genomic detection methodologies to measure the relative amount of tumor-derived nucleic acids in the blood of patients diagnosed with an early stage solid tumor who are either commencing, currently undergoing or have completed treatment. this approach will allow the investigators to develop a quantitative measure of therapy efficacy via the counting of the relative changes in tumor molecules over the course of treatment. the presence of circulating tumor-derived cfdna in the plasma of patients can potentially enable a non-invasive means of detecting the presence or absence of tumor, assessing tumor burden and characterizing tumor biology in patients with cancer. the ability to measure the distribution of circulating tumor dna may allow determination of a quantitative tumor load score in plasma that correlates to clinical tumor load. clinical tumor load is a measure of disease burden, and the investigators propose to test in this study whether the tumor load score can measure this disease burden. a simple, reliable measure of disease burden would have diverse utility during patient therapy.

Eligibility criteria:
inclusion criteria: 1. for all participants: * age 18 years or older * able to understand and grant informed consent * able to have their blood drawn at enrollment before surgery and 7 to 28 days after surgery for participants with early stage solid tumors: * diagnosed with an early stage (i-iii) solid tumor with curative intent surgery without neoadjuvant therapy planned for "healthy control" subgroup: * no prior or current diagnosis of any cancer. participants with prior in situ cancer or non-melanoma skin cancer will be allowed to participate but will not be included in the "healthy control" cohort and will be analyzed separately. exclusion criteria: * unable to grant informed consent or comply with all study procedures * diagnosed with a hematological malignancy (acute or chronic leukemia, myelodysplastic syndrome, myeloproliferative neoplasm, myeloma or lymphoma).

Keywords: solid tumor carcinoma sarcoma stage i stage ii stage iii
insulin sensitivity of the brain in pathogenesis of diabetes mellitus type 2

Conditions: Human Physiology of Energy Homeostasis

Summary: the purpose of the study is to investigate whether insulin sensitivity of the human brain correlates with insulin sensitivity of the liver.


Eligibility criteria:
inclusion criteria: * age 18-70 risk factor(s) for type 2 diabetes (e.g. overweight, family history of diabetes) exclusion criteria: * type 2 diabetes pregnancy acute or chronic diseases
treating h. pylori in parkinson's patients with motor fluctuations

Conditions: Parkinson's Disease; Helicobacter Infections; Motor Fluctuations

Summary: the purpose of this study is to determine whether treatment of h. pylori (an infection of the stomach) improves treatment effectiveness in patients with parkinson's disease and motor fluctuations.

previous investigations have demonstrated that treatment of helicobacter pylori with antibiotics leads to improved absorption and pharmacokinetics of levodopa. this may potentially benefit patients with parkinson's disease who have motor fluctuations, specifically excessive "off" time, when their levodopa is not working to control symptoms. we seek to identify the frequency of h. pylori infection in this population using standard lab assays and determine whether eradication with standard triple therapy results in improved clinical response to medication.

Eligibility criteria:
inclusion criteria: * adults diagnosed with idiopathic parkinson's disease, hoehn \& yahr stage 2-4 in the "off" state, with no other concomitant neurologic diseases. * stable (≥30 days) parkinson's disease therapy, with demonstrable medication efficacy, but with wearing off phenomenon present between levodopa doses (average off time ≥3 hours off time/day). * levodopa therapy required; any formulation (e.g. sinemet, sinemet cr, stalevo) is acceptable. parkinson's disease treatment may also include any of the following medications or classes: non-ergot dopamine agonists, comt inhibitors, mao-b inhibitors, amantadine, anticholinergics. * positive for h. pylori igg ab by serum elisa (before inclusion in randomized treatment arms). exclusion criteria: * current abdominal pain, unexplained nausea/vomiting, or gastrointestinal bleeding. * history of gastric cancer, peptic ulcer, duodenal ulcer, or other gastric or duodenal lesions. * history of previous gastric surgery. * history of previous brain surgery for parkinson's disease. * family history of gastric cancer. * prior treatment for h. pylori+ status. * recent use (previous 4 weeks) of proton-pump inhibitor, amoxicillin, or clarithromycin. * allergy or sensitivity to penicillin, amoxicillin, clarithromycin, or omeprazole. * use of drugs affecting gastric motility (e.g. domperidone, metoclopramide). * inability to tolerate or participate in testing in the morning in an "off" state. * inability to communicate effectively with study personnel in english. * pregnancy.

Keywords: parkinson's disease levodopa helicobacter pylori
multiple-dose study to evaluate the efficacy, safety and pharmacokinetics of bms-646256 in obese subjects

Conditions: Obesity

Summary: the purpose of this study is to learn if bms-646256 can cause weight loss in men and women who are: * overweight with high blood pressure or high cholesterol or * obese the safety of this treatment will also be studied


Eligibility criteria:
inclusion criteria: * men and women, ages ≥18 to ≤70 years old with a body mass index (bmi) ≥30 to ≤45 kg/m² or bmi \>27 to \<30 kg/m² with hypertension and/or dyslipidemia defined as: * hypertension defined as treatment with an antihypertensive agent or mean systolic blood pressure ≥140 and ≤160 mmhg and/or diastolic blood pressure ≥ 90 and ≤ 105 mmhg * dyslipidemia defined as stable dose treatment with a statin, fibrate or ezetimibe for ≥ 6 weeks and/or triglycerides ≥ 150 and ≤ 600 mg/dl, ldl ≥ 130 and ≤ 300 mg/dl, or hdl \< 40 mg/dl exclusion criteria: * type 1 or 2 diabetes mellitus * history of mi in the prior 6 months * history of heart failure * history of symptomatic arrhythmia * active hepatic disease * any documented muscle disease * history of neurological symptoms or disease (including but not limited to tremor, ataxia, dizziness, neuropathy, or episodes of confusion, history of seizures, stroke or tia) * known history of major psychiatric conditions (e.g. schizophrenia anxiety disorder, dementia or bipolar disorder as defined by dsm iv criteria) * history of depression or suicide attempt or ideation * previous history of surgical procedures for weight loss (e.g., stomach stapling, bypass) * uncontrolled blood pressure